Comparison of central adjudication of outcomes and onsite outcome assessment on treatment effect estimates

Cochrane Database of Systematic Reviews

Volumn 2016, Issue 3, 2016, Pages

  Ndounga Diakou, Lee Aymar ^a   Trinquart, Ludovic ^b   Hróbjartsson, Asbjørn ^c   Barnes, Caroline ^a   Yavchitz, Amelie ^a   Ravaud, Philippe ^a   Boutron, Isabelle ^a  

^a PARIS DESCARTES UNIVERSITY   (France)

^b HÔTEL DIEU   (France)

^c UNIVERSITY OF SOUTHERN DENMARK   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; CINAHL; CLINICAL ASSESSMENT; COCHRANE LIBRARY; CONTROLLED STUDY; EMBASE; EXPERIMENTAL THERAPY; FEMALE; HUMAN; MALE; MEDLINE; META ANALYSIS; MULTICENTER STUDY (TOPIC); PSYCINFO; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SINGLE BLIND PROCEDURE; SYSTEMATIC REVIEW; ADVISORY COMMITTEE; ODDS RATIO; OUTCOME ASSESSMENT; PROCEDURES; STANDARDS; TREATMENT OUTCOME;

ADVISORY COMMITTEES; HUMANS; MULTICENTER STUDIES AS TOPIC; ODDS RATIO; OUTCOME ASSESSMENT (HEALTH CARE); RANDOMIZED CONTROLLED TRIALS AS TOPIC; TREATMENT OUTCOME;

EID: 84977454439     PISSN: None     EISSN: 1469493X     Source Type: Journal    
DOI: 10.1002/14651858.MR000043.pub2     Document Type: Review

References (90)

1. ACTIVE Writing Group of the ACTIVE Investigators, Connolly S, Pogue J, Hart R, Pfeffer M, Hohnloser S, Chrolavicius S, et al. Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE W): a randomised controlled trial. Lancet 2006;367(9526):1903-12. [PUBMED: 16765759]
2. EINSTEIN Investigators, Bauersachs R, Berkowitz SD, Brenner B, Buller HR, Decousus H, Gallus AS, et al. Oral rivaroxaban for symptomatic venous thromboembolism. New England Journal of Medicine 2010;363(26):2499-510. [DOI: 10.1056/NEJMoa1007903; NCT00439725; NCT00440193]
3. Bennett-Guerrero E, Ferguson TB Jr, Lin M, Garg J, Mark DB, Scavo VA Jr, et al. SWIPE-1 Trial Group. Effect of an implantable gentamicin-collagen sponge on sternal wound infections following cardiac surgery: a randomized trial. JAMA 2010;304(7):755-62. [PUBMED: 20716738]
4. Bezafibrate Infarction Prevention (BIP) study. Secondary prevention by raising HDL cholesterol and reducing triglycerides in patients with coronary artery disease. Circulation 2000;102(1):21-7. [PUBMED: 10880410]
5. Bolland MJ, Barber A, Doughty RN, Grey A, Gamble G, Reid IR. Differences between self-reported and verified adverse cardiovascular events in a randomised clinical trial. BMJ Open 2013;3(3):pii: e002334. [DOI: 10.1136/bmjopen-2012-002334; PUBMED: 23512838]
6. Bresalier RS, Sandler RS, Quan H, Bolognese JA, Oxenius B, Horgan K, et al. Adenomatous Polyp Prevention on Vioxx (APPROVe) Trial Investigators. Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. New England Journal of Medicine 2005;352(11):1092-102. [PUBMED: 15713943]
7. Buller HR, Lensing AW, Prins MH, Agnelli G, Cohen A, Gallus AS, et al. Einstein-DVT Dose-Ranging Study investigators. A dose-ranging study evaluating once-daily oral administration of the factor Xa inhibitor rivaroxaban in the treatment of patients with acute symptomatic deep vein thrombosis: the Einstein-DVT Dose-Ranging Study. Blood 2008;112(6):2242-7. [PUBMED: 18621928]
8. EINSTEIN–PE Investigators, Büller HR, Prins MH, Lensin AW, Decousus H, Jacobson BF, Minar E, et al. Oral rivaroxaban for the treatment of symptomatic pulmonary embolism. New England Journal of Medicine 2012;366(14):1287-97. [PUBMED: 22449293]
9. Yusuf S, Pfeffer MA, Swedberg K, Granger CB, Held P, McMurray JJ, et al. CHARM Investigators and Committees. Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial. Lancet 2003;362(9386):777-81. [PUBMED: 13678871]
10. Yusuf S, Mehta SR, Xie C, Ahmed RJ, Xavier D, Pais P, et al. CREATE Trial Group Investigators. Effects of reviparin, a low-molecular-weight heparin, on mortality, reinfarction, and strokes in patients with acute myocardial infarction presenting with ST-segment elevation. JAMA 2005;293(4):427-35. [PUBMED: 15671427]
11. Yusuf S, Zhao F, Mehta SR, Chrolavicius S, Tognoni G, Fox KK, Clopidogrel in Unstable Angina to Prevent Recurrent Events Trial Investigators. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. New England Journal of Medicine 2001;345(7):494-502. [PUBMED: 11519503]
12. The EPIC Investigators. Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty. The EPIC Investigation. New England Journal of Medicine 1994;330(14):956-61. [PUBMED: 8121459]
13. Fiessinger JN, Huisman MV, Davidson BL, Bounameaux H, Francis CW, Eriksson H, et al. THRIVE Treatment Study Investigators. Ximelagatran vs low-molecular-weight heparin and warfarin for the treatment of deep vein thrombosis: a randomized trial. JAMA 2005;293(6):691-9. [PUBMED: 15701909]
14. Francis CW, Davidson BL, Berkowitz SD, Lotke PA, Ginsberg JS, Lieberman JR, et al. Ximelagatran versus warfarin for the prevention of venous thromboembolism after total knee arthroplasty. A randomized, double-blind trial. Annals of Internal Medicine 2002;137(8):648-55. [PUBMED: 12379064]
15. Gulizia M, Mangiameli S, Orazi S, Chiarandà G, Piccione G, Di Giovanni N, et a, PITAGORA Study Investigators. A randomized comparison of amiodarone and class IC antiarrhythmic drugs to treat atrial fibrillation in patients paced for sinus node disease: the Prevention Investigation and Treatment: A Group for Observation and Research on Atrial arrhythmias (PITAGORA) trial. American Heart Journal 2008;155(1)(1):100-7. [PUBMED: 18082498]
16. The global use of strategies to open occluded coronary arteries (GUSTO) IIb investigators. A comparison of recombinant hirudin with heparin for the treatment of acute coronary syndromes. The Global Use of Strategies to Open Occluded Coronary Arteries (GUSTO) IIb investigators. New England Journal of Medicine 1996;335(11):775-82. [PUBMED: 8778585]
17. Hata J, Arima H, Zoungas S, Fulcher G, Pollock C, Adams M, et al. ADVANCE Collaborative Group. Effects of the endpoint adjudication process on the results of a randomised controlled trial: the ADVANCE trial. PLoS One 2013;8(2):e55807. [PUBMED: 23390553]
18. Hawkey CJ, Weinstein WM, Smalley W, Gitton X, Sallstig P, Stricker K, et al. Effect of risk factors on complicated and uncomplicated ulcers in the TARGET lumiracoxib outcomes study. Gastroenterology 2007;133(1):57-64. [PUBMED: 17631131]
19. Hochman JS, Lamas GA, Buller CE, Dzavik V, Reynolds HR, Abramsky SJ, et al. Occluded Artery Trial Investigators. Coronary intervention for persistent occlusion after myocardial infarction. New England Journal of Medicine 2006;355(23):2395-407. [PUBMED: 17105759]
20. Yusuf S, Sleight P, Pogue J, Bosch J, Davies R, Dagenais G. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. New England Journal of Medicine 2000;342(3):145-53. [PUBMED: 10639539]
21. Lonn E, Yusuf S, Arnold MJ, Sheridan P, Pogue J, Micks M, et al. Heart Outcomes Prevention Evaluation (HOPE) 2 Investigators. Homocysteine lowering with folic acid and B vitamins in vascular disease. New England Journal of Medicine 2006;354(15):1567-77. [PUBMED: 16531613]
22. The IMPACT-II Investigators. Randomised placebo-controlled trial of effect of eptifibatide on complications of percutaneous coronary intervention: IMPACT-II. Integrilin to Minimise Platelet Aggregation and Coronary Thrombosis-II. Lancet 1997;349(9063):1422-8. [PUBMED: 9164315]
23. Kirwan BA, Lubsen J, de Brouwer S, Danchin N, Battler A, Bayes de Luna A, et al. ACTION (A Coronary disease Trial Investigating Outcome with Nifedipine GITS) investigators. Diagnostic criteria and adjudication process both determine published event-rates: the ACTION trial experience. Contemporary Clinical Trials 2007;28(6):720-9. [PUBMED: 17509947]
24. McMurray J, Solomon S, Pieper K, Reed S, Rouleau J, Velazquez E, et al. The effect of valsartan, captopril, or both on atherosclerotic events after acute myocardial infarction: an analysis of the Valsartan in Acute Myocardial Infarction Trial (VALIANT). Journal of the American College of Cardiology 2006;47(4):726-33. [PUBMED: 16487836]
25. Moss AJ, Schuger C, Beck CA, Brown MW, Cannom DS, Daubert JP, et al. MADIT-RIT Trial Investigators. Reduction in inappropriate therapy and mortality through ICD programming. New England Journal of Medicine 2012;367(24):2275-83. [PUBMED: 23131066]
26. Näslund U, Grip L, Fischer-Hansen J, Gundersen T, Lehto S, Wallentin L. The impact of an end-point committee in a large multicentre, randomized, placebo-controlled clinical trial: results with and without the end-point committee's final decision on end-points. European Heart Journal 1999;20(10):771-7. [PUBMED: 10329069]
27. Ninomiya T, Donnan G, Anderson N, Bladin C, Chambers B, Gordon G, et al. PROGRESS Collaborative Group. Effects of the end point adjudication process on the results of the Perindopril Protection Against Recurrent Stroke Study (PROGRESS). Stroke 2009;40(6):2111-5. [PUBMED: 19359647]
28. O'Connor CM, Gottlieb S, Bourque JM, Krause-Steinrauf H, Anand I, Anderson JL, et al. BEST Investigators. Impact of nonfatal myocardial infarction on outcomes in patients with advanced heart failure and the effect of bucindolol therapy. American Journal of Cardiology 2005;95(5):558-64. [PUBMED: 15721091]
29. Organization to Assess Strategies for Ischemic Syndromes (OASIS) Investigators. Comparison of the effects of two doses of recombinant hirudin compared with heparin in patients with acute myocardial ischemia without ST elevation: a pilot study. Circulation 1997;96(3):769-77. [PUBMED: 9264481]
30. Organisation to Assess Strategies for Ischemic Syndromes (OASIS-2) Investigators. Effects of recombinant hirudin (lepirudin) compared with heparin on death, myocardial infarction, refractory angina, and revascularisation procedures in patients with acute myocardial ischaemia without ST elevation: a randomised trial. Lancet 1999;353(9151):429-38. [PUBMED: 9989712]
31. Fifth Organization to Assess Strategies in Acute Ischemic Syndromes Investigators1, Yusuf S, Mehta SR, Chrolavicius S, Afzal R, Pogue J, Granger CB, et al. Comparison of fondaparinux and enoxaparin in acute coronary syndromes. New England Journal of Medicine 2006;354(14):1464-76. [PUBMED: 16537663]
32. Yusuf S, Mehta SR, Chrolavicius S, Afzal R, Pogue J, Granger CB, et al. OASIS-6 Trial Group. Effects of fondaparinux on mortality and reinfarction in patients with acute ST-segment elevation myocardial infarction: the OASIS-6 randomized trial. JAMA 2006;295(13):1519-30. [PUBMED: 16537725]
33. Kopple JD, Cheung AK, Christiansen JS, Djurhuus CB, El Nahas M, Feldt-Rasmussen B, et al. OPPORTUNITY: a large-scale randomized clinical trial of growth hormone in hemodialysis patients. Nephrology Dialysis Transplantation 2011;26(12):4095-103. [PUBMED: 21750157]
34. Mahaffey KW, Roe MT, Dyke CK, Newby LK, Kleiman NS, Connolly P, et al. Misreporting of myocardial infarction end points: results of adjudication by a central clinical events committee in the PARAGON-B trial. Second Platelet IIb/IIIa Antagonist for the Reduction of Acute Coronary Syndrome Events in a Global Organization Network Trial. American Heart Journal 2002;143(2):242-8. [PUBMED: 11835026]
35. Prince RL, Devine A, Dhaliwal SS, Dick IM. Effects of calcium supplementation on clinical fracture and bone structure: results of a 5-year, double-blind, placebo-controlled trial in elderly women. Archives of Internal Medicine 2006;166(8):869-75. [PUBMED: 16636212]
36. Mahaffey KW, Harrington RA, Akkerhuis M, Kleiman NS, Berdan LG, Crenshaw BS, et al. For the PURSUIT Investigators. Disagreements between central clinical events committee and site investigator assessments of myocardial infarction endpoints in an international clinical trial: review of the PURSUIT study. Current Controlled Trials in Cardiovascular Medicine 2001;2(4):187-94. [PUBMED: 11806794]
37. Home PD, Pocock SJ, Beck-Nielsen H, Curtis PS, Gomis R, Hanefeld M, et al. RECORD Study Team. Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial. Lancet 2009;373(9681):2125-35. [PUBMED: 19501900]
38. Schulman S, Kearon C, Kakkar AK, Mismetti P, Schellong S, Eriksson H, et al. RE-COVER Study Group. Dabigatran versus warfarin in the treatment of acute venous thromboembolism. New England Journal of Medicine 2009;361(24):2342-52. [PUBMED: 19966341]
39. Shumaker SA, Legault C, Rapp SR, Thal L, Wallace RB, Ockene JK, et al. WHIMS Investigators. Estrogen plus progestin and the incidence of dementia and mild cognitive impairment in postmenopausal women: the Women's Health Initiative Memory Study: a randomized controlled trial. JAMA 2003;289(20):2651-62. [PUBMED: 12771112]
40. Shumaker SA, Legault C, Kuller L, Rapp SR, Thal L, Lane DS, et al. Women's Health Initiative Memory Study. Conjugated equine estrogens and incidence of probable dementia and mild cognitive impairment in postmenopausal women: Women's Health Initiative Memory Study. JAMA 2004;291(24):2947-58. [PUBMED: 15213206]
41. Thomas SH, Drici MD, Hall GC, Crocq MA, Everitt B, Lader MH, et al. Safety of sertindole versus risperidone in schizophrenia: principal results of the sertindole cohort prospective study (SCoP). Acta Psychiatrica Scandinavica 2010;122(5):345-55. [PUBMED: 20384598]
42. Topol EJ, Leya F, Pinkerton CA, Whitlow PL, Hofling B, Simonton CA, et al. A comparison of directional atherectomy with coronary angioplasty in patients with coronary artery disease. The CAVEAT Study Group. New England Journal of Medicine 1993;329(4):221-7. [PUBMED: 8316266]
43. Verhamme P, Gunn S, Sonesson E, Peerlinck K, Vanassche T, Vandenbriele C, et al. Single-dose TB-402 or rivaroxaban for the prevention of venous thromboembolism after total hip replacement. A randomised, controlled trial. Thrombosis and Haemostasis 2013;109(6):1091-8. [PUBMED: 23615791]
44. Wallentin L, Becker RC, Budaj A, Cannon CP, Emanuelsson H, Held C, et al. PLATO Investigators, Freij A, Thorsén M. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. New England Journal of Medicine 2009;361(11):1045-57. [DOI: 10.1056/NEJMoa0904327; PUBMED: 19717846]
45. Warfarin Antiplatelet Vascular Evaluation Trial Investigators, Anand S, Yusuf S, Xie C, Pogue J, Eikelboom J, Budaj A, et al. Oral anticoagulant and antiplatelet therapy and peripheral arterial disease. New England Journal of Medicine 2007;357(3):217-27. [PUBMED: 17634457]
46. Winston DJ, Saliba F, Blumberg E, Abouljoud M, Garcia-Diaz JB, Goss JA, et al. 1263-301 Clinical Study Group. Efficacy and safety of maribavir dosed at 100 mg orally twice daily for the prevention of cytomegalovirus disease in liver transplant recipients: a randomized, double-blind, multicenter controlled trial. American Journal of Transplantation 2012;12(11):3021-30. [PUBMED: 22947426]
47. Wiviott SD, Braunwald E, McCabe CH, Montalescot G, Ruzyllo W, Gottlieb S, et al. TRITON-TIMI 38 Investigators. Prasugrel versus clopidogrel in patients with acute coronary syndromes. New England Journal of Medicine 2007;357(20):2001-15. [PUBMED: 17982182]
48. Arnold DM, Lauzier F, Rabbat C, Zytaruk N, Barlow Cash B, Clarke F, et al. PROTECT Investigators, on behalf of the Canadian Critical Care Trials Group and the Australian and New Zealand Intensive Care Society Clinical Trials Group. Adjudication of bleeding outcomes in an international thromboprophylaxis trial in critical illness. Thrombosis Research 2013;131(3):204-9. [PUBMED: 23317632]
49. Epstein AE, Powell J, Yao Q, Ocampo C, Lancaster S, Rosenberg Y, et al. In-hospital versus out-of-hospital presentation of life-threatening ventricular arrhythmias predicts survival: results from the AVID Registry. Antiarrhythmics Versus Implantable Defibrillators. Journal of the American College of Cardiology 1999;34(4):1111-6. [PUBMED: 10520799]
50. Heagerty A, Deverly A, Palmer C, Kaplinsky E, Salvetti A, Wahlgren NG, et al. The role of the critical event committee in a major cardiovascular outcome study. Blood Pressure 2002;11(6):339-44. [PUBMED: 12523676]
51. Kestle J, Milner R, Drake D. An assessment of observer bias in the shunt design trial. Pediatric Neurosurgery 1999;30(2):57-61. [PUBMED: 10325560]
52. Mahaffey KW, Wampole JL, Stebbins A, Berdan LG, McAfee D, Rorick TL. Strategic lessons from the clinical event classification process for the Assessment of Pexelizumab in Acute Myocardial Infarction (APEX-AMI) trial. Contemporary Clinical Trials 2011;32(2):178-87. [PUBMED: 21220052]
53. McGarvey LP, John M, Anderson JA, Zvarich M, Wise RA, TORCH Clinical Endpoint Committee. Ascertainment of cause-specific mortality in COPD: operations of the TORCH Clinical Endpoint Committee. Thorax 2007;62(5):411-5. [PUBMED: 17311843]
54. McGarvey LP, Magder S, Burkhart D, Kesten S, Liu D, Manuel RC, et al. Cause-specific mortality adjudication in the UPLIFT® COPD trial: findings and recommendations. Respiratory Medicine 2012;106(4):515-21. [DOI: 10.1016/j.rmed.2011.10.009; PUBMED: 22100536]
55. O'Connor CM, Fiuzat M, Lindenfeld J, Miller A, Lombardi C, Carson P, et al. Mode of death and hospitalization from the Second Follow-up Serial Infusions of Nesiritide (FUSION II) trial and comparison of clinical events committee adjudicated versus investigator reported outcomes. American Journal of Cardiology 2011;108(10):1449-57. [DOI: 10.1016/j.amjcard.2011.06.065; PUBMED: 21890092]
56. Petersen JL, Haque G, Hellkamp AS, Flaker GC, Mark Estes NA 3rd, Marchlinski FE, et al. MOST Clinical Events Committee. Comparing classifications of death in the Mode Selection Trial: agreement and disagreement among site investigators and a clinical events committee. Contemporary Clinical Trials 2006;27(3):260-8. [PUBMED: 16574497]
57. Slee A, Nasco E, Hart R. Effect of adjudication on cause of death in the affirm trial: evidence for bias by unblinded local investigators. Clinical Trials. 2010; Vol. 7:418–504.
58. Vejlstrup N, Clemmensen P, Steinmetz E, Krusell LR, Hansen KN, Christiansen I, et al. Blinded end point adjudication in the 'Danish multicenter randomized study on fibrinolytic therapy versus acute coronary angioplasty in acute myocardial infarction' (DANAMI-2 trial). Heart Drug 2003;3(3):127-33. [DOI: 10.1159/000073837]
59. Al-Shahi Salman R, Beller E, Kagan J, Hemminki E, Phillips RS, Savulescu J, et al. Increasing value and reducing waste in biomedical research regulation and management. Lancet 2014;383(9912):176-85. [PUBMED: 24411646]
60. Bagos PG. On the covariance of two correlated log-odds ratios. Statistics in Medicine 2012;31(14):1418-31. [PUBMED: 22302419]
61. Bellamy N, Kirwan J, Boers M, Brooks P, Strand V, Tugwell P, et al. Recommendations for a core set of outcome measures for future phase III clinical trials in knee, hip, and hand osteoarthritis. Consensus development at OMERACT III. Journal of Rheumatology 1997;24(4):799-802. [PUBMED: 9101522]
62. Boutron I, Estellat C, Guittet L, Dechartres A, Sackett DL, Hróbjartsson A, et al. Methods of blinding in reports of randomized controlled trials assessing pharmacologic treatments: a systematic review. PLoS Medicine 2006;3(10):e425.
63. Boutron I, Guittet L, Estellat C, Moher D, Hrobjartsson A, Ravaud P. Reporting methods of blinding in randomized trials assessing nonpharmacological treatments. PLoS Medicine 2007;4(2):e61. [PUBMED: 17311468]
64. Dechartres A, Boutron I, Roy C, Ravaud P. Inadequate planning and reporting of adjudication committees in clinical trials: recommendation proposal. Journal of Clinical Epidemiology 2009;62(7):695-702.
65. DerSimonian R, Laird N. Meta-analysis in clinical trials. Controlled Clinical Trials 1986;7(3):177-88. [PUBMED: 3802833]
66. Eriksson BI, Smith JJ, Caprini J, Hantel S, Clemens A, Feuring M, et al. Evaluation of the acute coronary syndrome safety profile of dabigatran etexilate in patients undergoing major orthopedic surgery: findings from four Phase 3 trials. Thrombosis Research 2012;130(3):396-402.
67. Granger CB, Vogel V, Cummings SR, Held P, Fiedorek F, Lawrence M, et al. Do we need to adjudicate major clinical events?. Clinical Trials 2008;5(1):56-60. [PUBMED: 18283081]
68. Hansson L, Hedner T, Dahlof B. Prospective randomized open blinded end-point (PROBE) study. A novel design for intervention trials. Prospective Randomized Open Blinded End-Point. Blood Pressure 1992;1(2):113-9. [PUBMED: 1366259]
69. Higgins JP, Altman DG, Gøtzsche PC, Jüni P, Moher D, Oxman AD, et al. The Cochrane Collaboration's tool for assessing risk of bias in randomised trials. BMJ 2011;343:d5928. [PUBMED: 22008217]
70. Horsley T, Dingwall O, Sampson M. Checking reference lists to find additional studies for systematic reviews. Cochrane Database of Systematic Reviews 2011, Issue 8. [DOI: 10.1002/14651858.MR000026.pub2]
71. Hróbjartsson A, Thomsen AS, Emanuelsson F, Tendal B, Hilden J, Boutron I, et al. Observer bias in randomised clinical trials with binary outcomes: systematic review of trials with both blinded and non-blinded outcome assessors. BMJ 2012;344:e1119.
72. Ioannidis JP, Greenland S, Hlatky MA, Khoury MJ, Macleod MR, Moher D, et al. Increasing value and reducing waste in research design, conduct, and analysis. Lancet 2014;383(9912):166-75. [PUBMED: 24411645]
73. Lewis JR, Zhu K, Prince RL. Adverse events from calcium supplementation: relationship to errors in myocardial infarction self-reporting in randomized controlled trials of calcium supplementation. Journal of Bone and Mineral Research 2012;27(3):719–22. [DOI: 10.1002/jbmr.1484]
74. Lopes RD, Dickerson S, Hafley G, Burns S, Tourt-Uhlig S, White J, et al. Methodology of a reevaluation of cardiovascular outcomes in the RECORD trial: study design and conduct. Amercan Heart Journal 2013;166(2):208-16 e28. [PUBMED: 23895802]
75. Mahaffey KW, Harrington RA, Akkerhuis M, Kleiman NS, Berdan LG, Crenshaw BS, et al. Systematic adjudication of myocardial infarction end-points in an international clinical trial. Current Controlled Trials in Cardiovascular Medicine 2001;2(4):180-6.
76. Mahaffey KW, Harrington RA, Akkerhuis M, Kleiman NS, Berdan LG, Crenshaw BS, et al. Disagreements between central clinical events committee and site investigator assessments of myocardial infarction endpoints in an international clinical trial: review of the PURSUIT study. Current Controlled Trials in Cardiovascular Medicine 2001;2(4):187-94.
77. Mahaffey KW, Roe MT, Dyke CK, Newby LK, Kleiman NS, Connolly P, et al. Misreporting of myocardial infarction end points: results of adjudication by a central clinical events committee in the PARAGON-B trial. Second Platelet IIb/IIIa Antagonist for the Reduction of Acute Coronary Syndrome Events in a Global Organization Network Trial. American Heart Journal 2002;143(2):242-8.
78. Moustgaard H, Bello S, Miller FG, Hróbjartsson A. Subjective and objective outcomes in randomized clinical trials: definitions differed in methods publications and were often absent from trial reports. Journal of Clinical Epidemiology 2014;67(12):1327-34.
79. Naslund U, Grip L, Fischer-Hansen J, Gundersen T, Lehto S, Wallentin L. The impact of an end-point committee in a large multicentre, randomized, placebo-controlled clinical trial: results with and without the end-point committee's final decision on end-points. European Heart Journal 1999;20(10):771-7. [PUBMED: 10329069]
80. Nissen SE. Rosiglitazone: a case of regulatory hubris. BMJ 2013;347:f7428. [24335808]
81. O'Connor CM, Gottlieb S, Bourque JM, Krause-Steinrauf H, Anand I, Anderson JL, et al. Impact of nonfatal myocardial infarction on outcomes in patients with advanced heart failure and the effect of bucindolol therapy. American Journal of Cardiology 2005;95(5):558-64.
82. Pogue J, Walter SD, Yusuf S. Evaluating the benefit of event adjudication of cardiovascular outcomes in large simple RCTs. Clinical Trials 2009;6(3):239-51. [PUBMED: 19528133]
83. Psaty BM, Prentice RL. Minimizing bias in randomized trials: the importance of blinding. JAMA 2010;304(7):793-4. [PUBMED: 20716744]
84. Savović J, Jones HE, Altman DG, Harris RJ, Jüni P, Pildal J, et al. Influence of reported study design characteristics on intervention effect estimates from randomized, controlled trials. Annals of Internal Medicine 2012;157(6):429-38.
85. Serebruany VL, Atar D. Viewpoint: Central adjudication of myocardial infarction in outcome-driven clinical trials--common patterns in TRITON, RECORD, and PLATO?. Thrombosis and Haemostasis 2012;108(3):412-4. [PUBMED: 22836596]
86. Stuck AK, Fuhrer E, Limacher A, Mean M, Aujesky D. Adjudication-related processes are underreported and lack standardization in clinical trials of venous thromboembolism: a systematic review. Journal of Clinical Epidemiology 2014;67(3):278-84. [PUBMED: 24290147]
87. Vannabouathong C, Sprague S, Bhandari M. Guidelines for fracture healing assessments in clinical trials. Part I: definitions and endpoint committees. Injury 2011;42(3):314-6.
88. Vannabouathong C, Saccone M, Sprague S, Schemitsch EH, Bhandari M. Adjudicating outcomes: fundamentals. Journal of Bone and Joint Surgery. American Volume 2012;94(Suppl 1):70-4. [PUBMED: 22810452]
89. Wood L, Egger M, Gluud LL, Schulz KF, Jüni P, Altman DG, et al. Empirical evidence of bias in treatment effect estimates in controlled trials with different interventions and outcomes: meta-epidemiological study. BMJ 2008;336(7644):601-5.
90. Ndounga Diakou LA, Trinquart L, Hróbjartsson A, Barnes C, Yavchitz A, Ravaud P, et al. Comparison of central adjudication of outcomes and onsite outcome assessment on treatment effect estimates. Cochrane Database of Systematic Reviews 2015, Issue 7. [DOI: 10.1002/14651858.MR000043]